GlassScriptPhysician profile
Ralph M Cincinnati
NPI 1174580716
$16,478.70
in general payments reported to CMS, 2019-2025
35 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,286 · 2022: $3,580 · 2023: $1,745 · 2024: $2,491 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,571 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,571.05 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $3,011.70 | 2021-2025 | Afrezza |
| Senseonics, Incorporated | $1,800.00 | 2021-2022 | |
| Lilly USA, LLC | $1,415.01 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,199.73 | 2021-2025 | Lokelma, Farxiga |
| Abbvie INC. | $1,116.24 | 2021-2025 | |
| Abbott Laboratories | $1,032.99 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $895.88 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $792.32 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $732.51 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $470.19 | 2022-2025 | |
| Amgen INC. | $445.95 | 2021-2025 | Repatha, Repatha |
| Insulet Corporation | $413.36 | 2021-2025 | Omnipod |
| Corcept Therapeutics | $358.17 | 2021-2025 | Korlym |
| Amarin Pharma, INC. | $346.74 | 2021-2023 | |
| Medtronic, INC. | $326.80 | 2022-2025 | Minimed 780g, Minimed 770g |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $303.98 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $279.80 | 2021-2023 | Steglatro, Steglujan |
| Xeris Pharmaceuticals, INC. | $226.61 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $207.84 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $185.84 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $172.25 | 2023-2025 | |
| Zealand Pharma US, INC. | $134.08 | 2021-2022 | |
| Cequr Corporation | $98.67 | 2021-2024 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.55 | 2021-2024 | Cycloset |
| Esperion Therapeutics, INC. | $79.13 | 2021-2022 | |
| Sequel Med Tech, LLC | $53.58 | 2025 | Twiist |
| Kowa Pharmaceuticals America, INC. | $51.82 | 2021 | |
| Becton, Dickinson and Company | $50.95 | 2022 | |
| Beta Bionics, INC. | $44.03 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Averitas Pharma INC. | $43.55 | 2025 | Qutenza |
| Alfasigma USA, INC. | $27.47 | 2021 | |
| Bigfoot Biomedical INC | $22.18 | 2022 | |
| Fresenius USA Marketing, INC. | $19.72 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.64 | 2022 | |
| Embecta Corp. | $13.42 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Cincinnati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.